Literature DB >> 2839142

Effect of 24,25-dihydroxyvitamin D3 on 1,25-dihydroxyvitamin D3 metabolism in calcium-deficient rats.

T Matsumoto1, K Ikeda, H Yamato, K Morita, I Ezawa, M Fukushima, Y Nishii, E Ogata.   

Abstract

The effect of 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] on 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] metabolism was examined in rats fed on a low-calcium diet. These rats exhibit hypocalcaemia, high urinary cyclic AMP excretion, a markedly elevated serum 1,25(OH)2D concentration and low serum concentrations of both 24,25(OH)2D and 25(OH)D. When the rats are treated orally with 1, 5 or 10 micrograms of 24,25(OH)2D3/100 g every day, there is a dramatic decrease in serum 1,25(OH)2D concentration in a dose-dependent manner concomitant with an increase in serum 24,25(OH)2D concentration. Serum calcium concentration and urinary cyclic AMP excretion are not significantly affected by the 24,25(OH)2D3 treatment, which suggests that parathyroid function is not affected by the 24,25(OH)2D3 treatment. The 25(OH)D3 1 alpha-hydroxylase activity measured in kidney homogenates is markedly elevated in rats on a low-calcium diet but is not affected by any doses of 24,25(OH)2D3. In contrast, recovery of intravenously injected [3H]1,25(OH)2D3 in the serum is decreased in 24,25(OH)2D3-treated rats. Furthermore, when [3H]1,25(OH)2D3 is incubated in vitro with kidney or intestinal homogenates of 24,25(OH)2D3-treated rats there is a decrease in the recovery of radioactivity in the total lipid extract as well as in the 1,25(OH)2D3 fraction along with an increase in the recovery of radioactivity in the water-soluble phase. These results are consistent with the possibility that 24,25(OH)2D3 has an effect on 1,25(OH)2D3 metabolism, namely that of enhancing the degradation of 1,25(OH)2D3. However, because a considerable proportion of the injected 24,25(OH)2D3 is expected to be converted into 1,24,25(OH)3D3 by renal 1 alpha-hydroxylase in 24,25(OH)2D3-treated rats, at least a part of the decrease in serum 1,25(OH)2D concentration may be due to a competitive inhibition by 24,25(OH)2D3 of the synthesis of 1,25(OH)2D3 from 25(OH)D3. Thus the physiological importance of the role of 24,25(OH)2D3 in regulating the serum 1,25(OH)2D concentration as well as the mechanism and metabolic pathway of degradation of 1,25(OH)2D3 remain to be clarified.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839142      PMCID: PMC1148911          DOI: 10.1042/bj2500671

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  31 in total

1.  A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors:  J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

2.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

3.  An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue.

Authors:  M Honma; T Satoh; J Takezawa; M Ui
Journal:  Biochem Med       Date:  1977-12

4.  Competitive protein-binding radioassay of 24,25-dihydroxyvitamin D in sera from normal and anephric subjects.

Authors:  J G Haddad; C Min; M Mendelsohn; E Slatopolsky; T J Hahn
Journal:  Arch Biochem Biophys       Date:  1977-08       Impact factor: 4.013

5.  Increased urate excretion after o,p'-DDD.

Authors:  G Reach; F Elkik; C Parry; P Corvol; P Milleiz
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

6.  24, 25-dihydroxyvitamin D is a metabolite of vitamin D essential for bone formation.

Authors:  A Ornoy; D Goodwin; D Noff; S Edelstein
Journal:  Nature       Date:  1978-11-30       Impact factor: 49.962

7.  Simplified method for the estimation of inorganic phosphorus in body fluids.

Authors:  H Goldenberg; A Fernandez
Journal:  Clin Chem       Date:  1966-12       Impact factor: 8.327

8.  Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.

Authors:  J M Canterbury; S Lerman; A J Claflin; H Henry; A Norman; E Reiss
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

9.  Vitamin D metabolites and bone mineralization in man.

Authors:  P Bordier; H Rasmussen; P Marie; L Miravet; J Gueris; A Ryckwaert
Journal:  J Clin Endocrinol Metab       Date:  1978-02       Impact factor: 5.958

10.  Vitamin D: two dihydroxylated metabolites are required for normal chicken egg hatchability.

Authors:  H L Henry; A W Norman
Journal:  Science       Date:  1978-09-01       Impact factor: 47.728

View more
  5 in total

1.  Association of increased active PTH(1-84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D.

Authors:  M Kurajoh; M Inaba; S Yamada; Y Imanishi; T Tsuchida; E Ishimura; Y Nishizawa
Journal:  Osteoporos Int       Date:  2008-02-01       Impact factor: 4.507

2.  Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat.

Authors:  T Naveh-Many; J Silver
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

3.  Identification of a vitamin D responsive element in the promoter of the rat cytochrome P450(24) gene.

Authors:  C N Hahn; D M Kerry; J L Omdahl; B K May
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

4.  Effect of 24R,25-dihydroxyvitamin D3 on the formation and function of osteoclastic cells.

Authors:  H Yamato; R Okazaki; T Ishii; E Ogata; T Sato; M Kumegawa; K Akaogi; N Taniguchi; T Matsumoto
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

5.  Preclinical safety and efficacy of 24R,25-dihydroxyvitamin D3 or lactosylceramide treatment to enhance fracture repair.

Authors:  Corine Martineau; Martin Kaufmann; Alice Arabian; Glenville Jones; René St-Arnaud
Journal:  J Orthop Translat       Date:  2020-04-27       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.